Table 2.
Response according to treatment group
| Total, N = 162 | Single fraction, N = 65 | Multiple fraction, N = 97 | P‐value | |
|---|---|---|---|---|
| Pain score response | ||||
| 4 wk | 129/162 (79.6%) | 50/65a (76.9%) | 79/97 (81.4%) | .394 |
| 12 wk | 138/159 (86.8%) | 54/63 (85.7%) | 84/96 (87.5%) | .938 |
| 24 wk | 136/158 (86.1%) | 51/62 (82.3%) | 85/96 (88.5%) | .228 |
| Pain score progression | ||||
| 4 wk | 6/162 (3.7%) | 4/65 (6.2%) | 2/97 (2.1%) | .176 |
| 12 wk | 5/159 (3.1%) | 2/63 (3.2%) | 3/96 (3.1%) | .986 |
| 24 wk | 11/158 (6.9%) | 4/62 (6.5%) | 7/96 (7.3%) | .839 |
| Analgesic score response | ||||
| 4 wk | 81/162 (50%) | 30/65 (46.2%) | 51/97 (52.6%) | .155 |
| 12 wk | 92/159 (57.9%) | 34/63 (54%) | 58/96 (60.4%) | .319 |
| 24 wk | 93/158 (58.9%) | 34/62 (54.8%) | 59/96 (61.5%) | .056 |
| Analgesic score progression | ||||
| 4 wk | 16/162 (9.9%) | 10/65 (15.4%) | 6/97 (6.2%) | .054 |
| 12 wk | 20/159 (12.6%) | 11/63 (17.5%) | 9/96 (9.4%) | .133 |
| 24 wk | 27/158 (17.1%) | 16/62 (9.9%) | 11/96 (11.5%) | .019b |
| International consensus endpoint | ||||
| 4 wk | ||||
| CR | 52/162 (32.1%) | 18/65 (27.7%) | 34/97 (35.1%) | |
| PR | 39/162 (24.1%) | 15/65 (23.1%) | 24/97 (24.7%) | |
| ORR | 92/162 (56.2%) | 33/65 (50.8%) | 58/97 (59.8%) | .364 |
| Progression | 54/162 (33.3%) | 22/65 (33.8%) | 32/97 (33.0%) | .910 |
| 12 wk | ||||
| CR | 55/159 (34.6%) | 21/63 (33.3%) | 34/96 (35.4%) | |
| PR | 44/159 (27.7%) | 18/63 (28.6%) | 26/96 (27.1%) | |
| ORR | 99/159 (62.3%) | 39/63 (61.9%) | 60/96 (62.5%) | .466 |
| Progression | 38/159 (23.9%) | 13/63 (20.6%) | 25/96 (26.0%) | .384 |
| 24 wk | ||||
| CR | 89/158 (56.3%) | 33/62 (53.2%) | 56/96 (58.3%) | |
| PR | 14/158 (8.9%) | 5/62 (8.1%) | 9/96 (9.4%) | |
| ORR | 103/158 (65.2%) | 38/62 (61.3%) | 65/96 (67.7%) | .259 |
| Progression | 28/158 (17.7%) | 10/62 (16.1%) | 18/96 (18.8%) | .599 |
CR, complete response; PR, partial response; ORR, overall response (CR + PR).
a
Number of patients within treatment group.
b
P < .05.